This clinical trial is focused on studying a skin condition called hidradenitis suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin, often in areas like the armpits and groin. The trial is testing a new treatment called amlitelimab, which is given as a solution for injection under the skin. Amlitelimab is a type of protein designed to help reduce inflammation and improve symptoms in people with moderate to severe forms of this condition.

The purpose of the study is to evaluate how effective and safe amlitelimab is for treating hidradenitis suppurativa. Participants in the study will receive either amlitelimab or a placebo, which looks like the treatment but does not contain the active substance. The study will follow participants over a period of time to observe any changes in their condition and to monitor for any side effects. The main goal is to see if participants experience a reduction in the severity of their symptoms.

Throughout the study, participants will have regular check-ups to assess their response to the treatment. This includes monitoring the number and size of skin lumps, as well as any changes in pain levels and overall quality of life. The study aims to provide valuable information on whether amlitelimab can be a beneficial treatment option for those suffering from hidradenitis suppurativa.